Sign In to View Organizational & Contract Pricing
Select a Size
About This Item
Linear Formula:
H2NCH2C6H10CO2H
CAS Number:
Molecular Weight:
157.21
Beilstein:
2207452
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24
grade
pharmaceutical primary standard
API family
tranexamic acid
manufacturer/tradename
USP
mp
>300 °C (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
SMILES string
NC[C@H]1CC[C@@H](CC1)C(O)=O
InChI
1S/C8H15NO2/c9-5-6-1-3-7(4-2-6)8(10)11/h6-7H,1-5,9H2,(H,10,11)/t6-,7-
InChI key
GYDJEQRTZSCIOI-LJGSYFOKSA-N
Gene Information
human ... PLG(5340)
Looking for similar products? Visit Product Comparison Guide
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Tranexamic acid USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Tranexamic Acid Tablets
- Tranexamic Acid Injection
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
Target Organs
Respiratory system
Storage Class Code
11 - Combustible Solids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Chih-Hsiang Chang et al.
Clinical orthopaedics and related research, 472(5), 1552-1557 (2014-01-05)
Systemic tranexamic acid can decrease blood loss and rates of transfusion in patients undergoing total hip arthroplasty (THA). However, the efficacy of topical tranexamic acid in THA has only recently been characterized in a small number of studies. The purpose
Baohui Yang et al.
PloS one, 8(2), e55436-e55436 (2013-02-21)
Tranexamic acid (TXA) is well-established as a versatile oral, intramuscular, and intravenous (IV) antifibrinolytic agent. However, the efficacy of IV TXA in reducing perioperative blood transfusion in spinal surgery is poorly documented. We conducted a meta-analysis of randomized controlled trials
Zhi-Jun Li et al.
European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society, 22(9), 1950-1957 (2013-05-10)
The present meta-analysis aimed at assessing the effectiveness and safety of tranexamic acid (TXA) in reducing blood loss and transfusion in spinal surgery. Systematic searches of all studies published through March 2012 were identified from PubMed, EMBase, Cochrane library, Science
K Ker et al.
The British journal of surgery, 100(10), 1271-1279 (2013-07-11)
Tranexamic acid (TXA) reduces blood transfusion in surgery but the extent of the reduction in blood loss and how it relates to the dose of TXA is unclear. A systematic review of randomized trials was performed. Data were extracted on
Anshul Dahuja et al.
The Journal of arthroplasty, 29(4), 733-735 (2013-11-05)
Total knee arthroplasty(TKA) is associated with extensive postoperative blood loss. Despite various studies proving the efficacy of Tranexamic Acid (TEA) with single or multiple boluses of different sizes with or without subsequent infusions, no consensus has been reached on the
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service